Vulcan Value Partners LLC Has $26.58 Million Stake in Medpace Holdings, Inc. $MEDP

Vulcan Value Partners LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 76.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,306 shares of the company’s stock after selling 152,866 shares during the quarter. Medpace makes up about 0.5% of Vulcan Value Partners LLC’s holdings, making the stock its 29th largest position. Vulcan Value Partners LLC’s holdings in Medpace were worth $26,580,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of MEDP. AQR Capital Management LLC grew its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares during the last quarter. Invesco Ltd. grew its stake in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after acquiring an additional 60,883 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada dropped their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets reduced their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Robert W. Baird dropped their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $460.20 on Friday. Medpace Holdings, Inc. has a 1 year low of $301.90 and a 1 year high of $628.92. The company has a market capitalization of $13.14 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.33 and a beta of 1.18. The business has a fifty day moving average price of $452.12 and a two-hundred day moving average price of $499.49.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.